GlassScriptPhysician profile
Lani P Vu
NPI 1386669877
$4,990.34
in general payments reported to CMS, 2019-2025
27 companies · $948 in 2025
The $948 reported for 2025 was more than what 76% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $997 · 2020: $690 · 2021: $960 · 2022: $578 · 2023: $488 · 2024: $329 · 2025: $948.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,765.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,765.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $1,334.59 | 2019-2025 | Clareon, Clareon Panoptix Pro, Rocklatan |
| Allergan, INC. | $475.12 | 2019-2022 | |
| Abbvie INC. | $446.98 | 2022-2025 | Lumigan, Alphagan P, Durysta |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $422.08 | 2019-2021 | |
| Biotissue Holdings INC. | $383.26 | 2024-2025 | |
| Aerie Pharmaceuticals, INC. | $305.41 | 2019-2021 | |
| Bausch & Lomb Americas INC. | $295.34 | 2022-2025 | Vyzulta, Miebo, Xiidra |
| Kala Pharmaceuticals, INC. | $263.49 | 2019-2022 | |
| Sight Sciences, INC. | $184.77 | 2021-2025 | Omni Surgical System, Sion Surgical Instrument |
| Dompe US, INC. | $172.21 | 2022-2025 | Oxervate |
| Sun Pharmaceutical Industries INC. | $101.91 | 2021-2023 | Cequa |
| Johnson & Johnson Surgical Vision, INC. | $93.60 | 2019-2021 | |
| Mallinckrodt Hospital Products INC. | $88.86 | 2021 | |
| Glaukos Corporation | $76.64 | 2023-2025 | Istent Trabecular Micro-Bypass System Model Is3, Istent Inject Trabecular Micro-Bypass System, Istent Inject Trabecular Micro-Bypass System |
| Ocular Therapeutix, INC. | $51.16 | 2020-2021 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Thea Pharma INC. | $46.15 | 2023-2025 | Iyuzeh |
| Rayner Intraocular Lenses Limited | $41.30 | 2025 | Omidria, Rayone Emv, Rayone Spheric |
| Tarsus Pharmaceuticals, INC. | $31.97 | 2024 | Xdemvy |
| Ivantis, INC | $30.69 | 2021 | |
| Eyevance Pharmaceuticals LLC | $20.32 | 2020 | |
| Merz North America, INC. | $19.78 | 2023 | Xeomin |
| Horizon Therapeutics Plc | $19.66 | 2021 | |
| Harrow Eye, LLC | $19.47 | 2025 | Vevye |
| Oyster Point Pharma, INC. | $18.93 | 2022 | |
| Alcon Research LLC | $17.49 | 2019 | |
| New World Medical,INC. | $17.03 | 2025 | Clearpath, Kahook Dual Blade, Via360 |
| Galderma Laboratories, L.P. | $12.13 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lani Vu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.